# A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

> **NCT01678872** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Oxford BioMedica** · enrollment: 18 (estimated)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** RetinoStat

## Key facts

- **NCT ID:** NCT01678872
- **Lead sponsor:** Oxford BioMedica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-08
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01678872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01678872, "A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01678872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*